DSIPДельта-сон-индуцирующий пептид
Delta sleep-inducing peptide (DSIP) is a nine-amino-acid peptide, Trp–Ala–Gly–Gly–Asp–Ala–Ser–Gly–Glu. Its name comes from early sleep experiments. Later studies examined sleep, pain and withdrawal.
What the studies found
Controlled study in people · 1992
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.
- Objective sleep
- Higher efficiency and shorter latency, described as weak effectsAuthors note possible contribution from incidental placebo-group changes
- Subjective sleep quality
- No changeNo numerical sleep-minute difference in the abstract
In 16 chronic-insomnia patients, DSIP produced weak objective sleep differences and no consistent subjective sleep benefit; the authors found little likely therapeutic value.
Study notes · methods, sources and limitations
Participants or model 16 patients; double-blind matched-pairs parallel groups
Design Double-blind matched-pairs parallel comparison: 8 DSIP, 8 glucose placebo; five laboratory nights.
- Participants
- 8 DSIP; 8 placebo
- Studied schedule
- 25 nmol/kg IV before nights 3, 4 and 5
Important limitations
- Small, brief study; selected statistically significant endpoints do not establish a meaningful overall benefit.
- Design figures are available; objective effect sizes in minutes and confidence intervals are not. The original authors did not infer a major therapeutic benefit.
Neuropsychobiology 26(4):193-197 · Indexed abstract
Animal research · 2014
Deltaran maternal-exposure abstract reports 96% offspring survival
Study of multiple preparations
- Reported survival
- Deltaran 96%; Pinealon 94%No n, uncertainty, untreated-hypoxia rate or numerical Cortexin survival supplied
- Caspase-3 conflict
- Deltaran+hypoxia is described as +144% in cortex and +109% in brainstem, then as remaining at control levelBoth statements occur in the same abstract; do not resolve by assumptionFirst sentence: p<0.0001 and p<0.001, respectively
Deltaran, a DSIP-containing preparation with glycine, had 96% reported offspring survival in the 2014 conference abstract. Group sizes and an untreated-hypoxia survival rate are missing; the biochemical result is internally contradictory.
Study notes · methods, sources and limitations
Participants or model 21-day-old outbred rat offspring; seven listed treatment groups; no group sizes supplied
Design Maternal intraperitoneal exposure throughout pregnancy. Daily hypobaric hypoxia on gestation days 13–20, 66.41 kPa for three hours. Offspring Morris maze and cortical/brainstem caspase-3 at day 21.
Important limitations
- Formulation-level animal findings cannot be assigned to isolated DSIP or treated as human pregnancy-safety evidence.
- Conference abstract with missing denominators and an internally inconsistent biochemical result; not a clinical trial. Deltaran is a DSIP-containing formulation with glycine; results are not proof for isolated DSIP. Formulation mass versus active-peptide mass is not resolved by this abstract. Shared Rostov authors and models may overlap the 2012 papers and dissertations; no pooled sample or independent-replication count is calculated.
X International Congress “Neuroscience for Medicine and Psychology”, Sudak, 2–12 June 2014, pp.233–234 · Conference abstract
Animal research · 1999
DSIP across hypoxia, swimming, immobilization and audiogenic stress
- Monoamine time course
- Selected changes observed for up to 5 days after an injectionMeasurements of brain neurochemistry; not drug exposure or human duration of action.
- Forced swimming
- Longer time before fatigue describedNo verified numerical swim-time contrast in accessible conclusions.
- Other stress models
- Changes in leukocyte pattern, lipid peroxidation and membrane measuresHypoxia, restricted movement and audiogenic stress; distinct experiments.
The author describes brain monoamine changes observed up to five days after a DSIP injection and delayed fatigue in forced swimming.
Study notes · methods, sources and limitations
Participants or model Animal experiments in multiple stress models; group counts not verified in accessible text
Design Animal experiments in multiple stress models; group counts not verified in accessible text
Important limitations
- Five days refers to observation of selected biochemical changes, not measured half-life or five days of benefit.
- Five days refers to observation of selected biochemical changes, not measured half-life or five days of benefit. Swimming time and survival magnitudes and adverse effects require full results tables.
- An archival stress-response hypothesis. Exact effects and dose schedules remain unresolved.
Rostov-on-Don doctoral dissertation, 338 pp. · Dissertation
About DSIP
Names in this research collection
Delta sleep-inducing peptide · Delta-sleep inducing peptide · WAGGDASGE
Identity / background source ↗
Research background
A peptide first characterized in Swiss sleep research and later studied in Soviet/Russian analogue and stress-adaptation programs. Ordinary DSIP, modified analogues and piracetam combinations have distinct evidence.
Pregnancy and offspring research
Deltaran, a DSIP-containing preparation with glycine, had 96% reported offspring survival in the 2014 conference abstract. Group sizes and an untreated-hypoxia survival rate are missing; the biochemical result is internally contradictory.
Formulation-level animal findings cannot be assigned to isolated DSIP or treated as human pregnancy-safety evidence.
Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗
More study findings
Animal research · 2006
Deltaran and avoidance learning in animals
Study of multiple preparations
- Conditioned swimming avoidance
- Acquisition and retention changedThe original abstract gives no numerical effect or group size.
- Spontaneous behavior
- More horizontal and vertical movement and less time freezingDirection only from the original abstract. Swimming was an avoidance task.
The abstract reports changes in acquisition and retention of an active swimming-avoidance response, more spontaneous movement and less freezing with Deltaran.
Study notes · methods, sources and limitations
Participants or model Laboratory animals in conditioned avoidance and locomotor behavior experiments. Group sizes unverified.
Design Laboratory animals in conditioned avoidance and locomotor behavior experiments. Group sizes unverified.
Important limitations
- Deltaran contains DSIP and glycine. The contribution of isolated DSIP was not established. Original dose, groups and numerical outcomes remain unverified.
- An animal learning and behavior experiment. Its abstract supplies no athletic endurance endpoint.
Medline.ru. 7:47–54, article 5 · Medline.ru. 7:47–54, article 5
Animal research · 2017
Deltaran and plasma superoxide dismutase in rats
Study of multiple preparations
- Plasma superoxide dismutase activity
- +28.6% in males and +21.1% in femalesVersus corresponding controls.p<0.05 as reported
- Plasma protein and total lipids
- Protein +14.8% in males and total lipids +20.2% in femalesVersus corresponding controls. The reverse sex-specific comparisons showed no reported difference.p<0.05 as reported
- Female plasma phospholipid share
- −21.3%Share of plasma lipids, a separate measure from total lipids.
Plasma superoxide dismutase activity increased 28.6% in male rats and 21.1% in females compared with controls.
Study notes · methods, sources and limitations
Participants or model Male and female laboratory rats. The abstract prints n=6 per group.
Design Male and female rats received intranasal Deltaran for five days and were compared with controls. The abstract reports six per group and measures plasma protein, lipids and antioxidant enzyme activity.
Important limitations
- Small conference experiment and an unusually high printed formulation dose. No performance, endurance or human endpoint was measured.
- These biomarker changes describe the tested DSIP-plus-glycine formulation.
Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22 · Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22
Animal research · 2006
Age and baseline anxiety in Lysenko’s peptide stress models
Study of multiple preparations
- High-anxiety young rats
- Vilon and GVS-111 were highlighted in the author’s conclusionsOriginal group-level numerical estimates and doses still need retrieval.
- Stress-response direction
- Favorable and unfavorable responses describedThe author discusses this for GVS-111 and an experimental preparation called NKT. NKT identity remains unresolved.
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
Study notes · methods, sources and limitations
Participants or model Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
Design Hypokinesia, hypoxia and exertion models, with behavioral, immune and oxidative endpoints. Twenty-four-hour hypokinesia was one stress protocol.
Important limitations
- Potential overlap with narrower author-network dissertations, including Morgul and Rudenko. Outcomes cannot be pooled or assigned to humans.
- A mechanistic program on stress response. The dissertation-level conclusion does not isolate all preparation-specific effects.
Doctoral dissertation, 244 pp., introduction and conclusions · Doctoral dissertation, 244 pp., introduction and conclusions
Comparison in people · 2008
Climatic chamber workload by condition
Study of multiple preparations
- Deltaran · cold (n=18)
- 196 → 217 WSeparate comparison. The author reports a significant increase from the pre-chamber measure.
Reported cycling work capacity in healthy men aged 20–24.
Study notes · methods, sources and limitations
Participants or model 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
Design Tabai climatic chamber: −10°C with 2.5 m/s airflow, +45°C at 80% humidity, or 3,000 m simulated altitude. The abstract specifies 40 minutes for cold and heat and 90 minutes at altitude within a longer chamber session.
Important limitations
- Related reports have overlapping results and group differences before exposure.
- Pre-chamber values reflect the testing protocol and are not established drug-free baselines. Small groups and multiple outcomes limit interpretation. Related 2007 journal and conference reports share investigators, treatments and chamber conditions. Matching workload means indicate overlap.
- The ledger uses the 301-person dissertation total once for these related reports.
Development and Study of New Meteoadaptogens, Kirov Military Medical Academy doctoral author abstract · Original dissertation author abstract
Animal research · 2009
Rat behavioral assays: DSIP-containing Deltaran
Study of multiple preparations
- Deltaran · grooming
- Grooming reactions increasedThe report tested Deltaran, a DSIP-containing formulation; this observation is not assigned to isolated DSIP.
Separate comparisons in an assay battery.
Study notes · methods, sources and limitations
Participants or model 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Design 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
- Reported study exposure
- 0.1 mg/kg intraperitoneally in the rat study.
Important limitations
- Deltaran was tested as a formulation. This is not a result for isolated DSIP.
- Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery. Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred. The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.
- Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.
Medical Academic Journal, 2009; publisher article 9357 · Original journal article
Animal research · 2004
DSIP analogues ID-1, ID-3 and ID-8 in age-stratified rat stress models
Study of multiple preparations
- Analogue identities
- ID-1, ID-3 and ID-8 tested separately from parent DSIP and piracetamAnalogue codes are reported; sequence-level identity was not independently resolved.
- Age and oxidative response
- ID-3 and piracetam were highlighted in old rats, including slower MDA formationQualitative conclusions only; no verified magnitude.
- Other endpoints
- Leukocyte profile and chromosomal-aberration outcomes varied by analogue and ageRestricted-movement model; biochemical and cytogenetic effects rather than sport performance.
The dissertation describes analogue- and age-dependent changes in leukocytes, oxidative markers and chromosome damage. ID-3 and piracetam were highlighted in older rats.
Study notes · methods, sources and limitations
Participants or model Rats of different ages under intact and restricted-movement conditions; DSIP and piracetam served as distinct comparators
Design Rats of different ages under intact and restricted-movement conditions; DSIP and piracetam served as distinct comparators
Important limitations
- Sequence identities, exact comparative estimates and doses need original table recovery.
- Sequence identities, exact comparative estimates and doses need original table recovery. The activity of these analogues does not establish an effect of DSIP itself or efficacy in humans.
- The primary value is a lead for analogue-specific research; the parent peptide and analogues remain distinct.
Candidate dissertation, 152 pp.; Makhachkala author abstract, 22 pp. · Dissertation
Controlled study in people · 1987
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.
- Sleep and daytime performance
- Reported improvements; numerical changes not suppliedSleep effects reportedly persisted on the first placebo post-treatment night
A 14-person placebo-controlled insomnia report described improved sleep and daytime performance over seven nights of DSIP, without giving numerical sleep or performance effect sizes in its abstract.
Study notes · methods, sources and limitations
Participants or model 14 middle-aged patients with chronic insomnia
Design 14 middle-aged chronic insomniacs; double-blind placebo-controlled administration and polysomnography.
- Participants
- 14 chronic-insomnia patients
- Observation schedule
- 7 successive treatment nights; daytime testing before and after 6 injections
Important limitations
- Small sample and short follow-up; allocation and complete methods require appraisal.
- This positive report is shown alongside the separate weak/neutral DSIP comparisons; their findings should not be pooled without full methods.
European neurology 27(2):120-129 · Indexed abstract
Controlled study in people · 1987
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.
- Awakenings and wake time
- Decreased during DSIP, without significant baseline or placebo differencesAlso applies to NREM latency and waking after sleep onset
- NREM and stage 2 sleep
- Nominal differences versus placebo, with the same differences already present at baseline
- Slow-wave and REM sleep
- Not modified
A double-blind crossover study found little clinically significant sleep improvement with DSIP; some nominal sleep-stage differences were already present at baseline.
Study notes · methods, sources and limitations
Participants or model Patients with chronic insomnia; double-blind crossover
Design Insomnia patients studied over four nights with polysomnography; sample size not stated in the abstract.
- Studied exposure
- 25 nmol/kg intravenously; four-night crossover
Important limitations
- Baseline differences complicate interpretation; sample size is not provided in the indexed abstract.
- The abstract contains no sleep-duration effect sizes or arm-level counts. Its conclusion is limited clinical significance.
International journal of clinical pharmacology research 7(2):105-110 · Indexed abstract
Performance research in context
- Compound class
- Experimental nonapeptide
- Research collection
- Neuropeptide research · editorial grouping
- Institutions in linked studies
- Neurocybernetics Institute, Rostov State University · Severtsov Institute of Ecology and Evolution, Russian Academy of Sciences
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Small insomnia studies with conflicting results; uncontrolled withdrawal report
Study methods
Short studies, baseline imbalances and incomplete full-text appraisal
Independent replication
Animal analogue results do not replicate ordinary DSIP efficacy; overlapping reports need checking
Source access
Indexed abstracts, original-paper repository and critical-review full text
Safety evidence
Long-term safety and safety of marketed preparations are not established by these records
Open a topic for the evidence assessment.
Findings by study
Animal research · 2006
Deltaran and avoidance learning in animals
The abstract reports changes in acquisition and retention of an active swimming-avoidance response, more spontaneous movement and less freezing with Deltaran.
Study notes and original source
Deltaran and avoidance learning in animals
· Medline.ru. 7:47–54, article 5
Format: Original journal abstract. Full PDF tables unavailable. · Reviewed: Reported methods, results and evidence limitations
G. G. Dmitriev, E. Yu. Bonitenko, M. B. Ivanov, V. A. Basharin · Medline.ru. 7:47–54, article 5
The abstract reports changes in acquisition and retention of an active swimming-avoidance response, more spontaneous movement and less freezing with Deltaran.
Results and tables
Reported findings and study design
The abstract reports changes in acquisition and retention of an active swimming-avoidance response, more spontaneous movement and less freezing with Deltaran.
Laboratory animals in conditioned avoidance and locomotor behavior experiments. Group sizes unverified.
Population or model Laboratory animals in conditioned avoidance and locomotor behavior experiments. Group sizes unverified.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Conditioned swimming avoidance | Acquisition and retention changed | The original abstract gives no numerical effect or group size. |
| Spontaneous behavior | More horizontal and vertical movement and less time freezing | Direction only from the original abstract. Swimming was an avoidance task. |
An animal learning and behavior experiment. Its abstract supplies no athletic endurance endpoint.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- Laboratory animals in conditioned avoidance and locomotor behavior experiments. Group sizes unverified.
- Source reviewed
- Original journal abstract. Full PDF tables unavailable.
Study limitations
- Deltaran contains DSIP and glycine. The contribution of isolated DSIP was not established. Original dose, groups and numerical outcomes remain unverified.
Reviewed 2026-11-09.
Animal research · 2017
Deltaran and plasma superoxide dismutase in rats
Plasma superoxide dismutase activity increased 28.6% in male rats and 21.1% in females compared with controls.
Study notes and original source
Deltaran and plasma superoxide dismutase in rats
· Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22
Format: Original 2017 Regulatory Neuropeptides conference abstract, pp. 21–22 · Reviewed: Reported methods, results and evidence limitations
S. G. Dagaev, L. G. Kubarskaya, V. A. Kashuro · Reviews of Clinical Pharmacology and Drug Therapy. 15(Suppl. 2):21–22
Plasma superoxide dismutase activity increased 28.6% in male rats and 21.1% in females compared with controls.
Results and tables
Reported findings and study design
Plasma superoxide dismutase activity increased 28.6% in male rats and 21.1% in females compared with controls.
Male and female rats received intranasal Deltaran for five days and were compared with controls. The abstract reports six per group and measures plasma protein, lipids and antioxidant enzyme activity.
Population or model Male and female laboratory rats. The abstract prints n=6 per group.
Protocol information
Intranasal Deltaran for five days. The abstract prints 150 mg/kg for the formulation. The unit and the mass of isolated DSIP are unconfirmed.
Protocol source ↗ · Original 2017 Regulatory Neuropeptides conference abstract, pp. 21–22
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Plasma superoxide dismutase activity | +28.6% in males and +21.1% in females | Versus corresponding controls. · p<0.05 as reported |
| Plasma protein and total lipids | Protein +14.8% in males and total lipids +20.2% in females | Versus corresponding controls. The reverse sex-specific comparisons showed no reported difference. · p<0.05 as reported |
| Female plasma phospholipid share | −21.3% | Share of plasma lipids, a separate measure from total lipids. |
These biomarker changes describe the tested DSIP-plus-glycine formulation.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- Male and female laboratory rats. The abstract prints n=6 per group.
- Source reviewed
- Original 2017 Regulatory Neuropeptides conference abstract, pp. 21–22
Study limitations
- Small conference experiment and an unusually high printed formulation dose. No performance, endurance or human endpoint was measured.
Reviewed 2026-11-09.
Animal research · 2006
Age and baseline anxiety in Lysenko’s peptide stress models
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
Study notes and original source
Age and baseline anxiety in Lysenko’s peptide stress models
· Doctoral dissertation, 244 pp., introduction and conclusions
Format: Author’s abstract transcription. Full dissertation and underlying records unavailable. · Reviewed: Reported methods, results and evidence limitations
A. V. Lysenko · Doctoral dissertation, 244 pp., introduction and conclusions
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
Results and tables
Reported findings and study design
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
Hypokinesia, hypoxia and exertion models, with behavioral, immune and oxidative endpoints. Twenty-four-hour hypokinesia was one stress protocol.
Population or model Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| High-anxiety young rats | Vilon and GVS-111 were highlighted in the author’s conclusions | Original group-level numerical estimates and doses still need retrieval. |
| Stress-response direction | Favorable and unfavorable responses described | The author discusses this for GVS-111 and an experimental preparation called NKT. NKT identity remains unresolved. |
A mechanistic program on stress response. The dissertation-level conclusion does not isolate all preparation-specific effects.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
- Source reviewed
- Author’s abstract transcription. Full dissertation and underlying records unavailable.
Study limitations
- Potential overlap with narrower author-network dissertations, including Morgul and Rudenko. Outcomes cannot be pooled or assigned to humans.
Reviewed 2026-11-09.
Comparison in people · 2008
Ganapolsky climate chambers: Cortexin, Noopept and related comparators
Reported cycling work capacity in healthy men aged 20–24.
Study notes and original source
Ganapolsky climate chambers: Cortexin, Noopept and related comparators
· Original dissertation author abstract
Format: Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending. · Reviewed: Reported methods, results and evidence limitations
V. P. Ganapolsky · Development and Study of New Meteoadaptogens, Kirov Military Medical Academy doctoral author abstract
In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.
Results and tables
Reported findings and study design
In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.
Tabai climatic chamber: −10°C with 2.5 m/s airflow, +45°C at 80% humidity, or 3,000 m simulated altitude. The abstract specifies 40 minutes for cold and heat and 90 minutes at altitude within a longer chamber session.
Population or model 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
Dose, route and schedule
Intranasal amounts in the author abstract: Cortexin 0.5 mg, Noopept 0.1 mg, Cerebrolysin 43 mg, Dilept 0.1 mg, Semax 0.2 mg and Deltaran 20 mg. Oral Vinpotropil contained piracetam 400 mg and vinpocetine 5 mg. Arms and testing series differ.
Protocol source ↗ · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cortexin · cold (n=17) | 155 → 210 W vs 159 → 162 W with placebo | Before chamber to during exposure; the 210 W mean is marked p<0.05 versus placebo and historical controls. |
| Noopept · heat (n=18) | 182 → 188 W vs 164 → 152 W with placebo | Before chamber to during exposure; the 188 W mean is marked p<0.05 versus placebo. |
| Cortexin · simulated altitude | 170 → 170 W vs 162 → 154 W with placebo | |
| Cerebrolysin · heat (n=17) | 194 → 138 W vs 164 → 152 W with placebo | |
| Dilept · cold (n=16) | 182 W during exposure | The author reports 12% higher than the historical untreated control. |
| Semax · cold (n=17) | 195 → 161 W | Separate comparison. The in-chamber group mean was near control. |
| Deltaran · cold (n=18) | 196 → 217 W | Separate comparison. The author reports a significant increase from the pre-chamber measure. |
Selected in-chamber PWC₁₇₀ means (W)
| Group | Cold | Heat | Simulated altitude |
|---|---|---|---|
| Cortexin (n=17) | 210 | 155 | 170 |
| Noopept (n=18) | 189 | 188 | 197 |
| Cerebrolysin (n=17) | 157 | 138 | 152 |
| Placebo (n=9) | 162 | 152 | 154 |
PWC₁₇₀ is the cycling workload at 170 beats/min. These are descriptive group means.
The ledger uses the 301-person dissertation total once for these related reports.
Source for these results ↗ · Reviewed 2026-11-17
- Population / setting
- 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
- Source reviewed
- Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
Study limitations
- Pre-chamber values reflect the testing protocol and are not established drug-free baselines. Small groups and multiple outcomes limit interpretation.
- Related 2007 journal and conference reports share investigators, treatments and chamber conditions. Matching workload means indicate overlap.
Reviewed 2026-11-17.
Animal research · 2009
Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin
Separate comparisons in an assay battery.
Study notes and original source
Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin
· Original journal article
Format: Publisher full-text methods and results narrative; original PDF tables not recovered · Reviewed: Reported methods, results and evidence limitations
P. D. Shabanov et al. · Medical Academic Journal, 2009; publisher article 9357
Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.
Results and tables
Reported findings and study design
Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.
192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Population or model 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Dose, route and schedule
Intraperitoneal doses: 1 mg/kg Cortexin, Cerebrolysin, Cortagen, Oleyl-Cortagen, Noopept and Dilept; 0.1 mg/kg Deltaran, Semax and Selank; piracetam 200 mg/kg. General behavior tests 30–40 minutes post-dose; self-stimulation measured 15–20 minutes post-dose.
Protocol source ↗ · Publisher full-text methods and results narrative; original PDF tables not recovered
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Oleyl-Cortagen · self-stimulation | +32% in lateral-hypothalamic pedal presses | Reported relative increase, not an endurance or strength endpoint. |
| Cortexin · self-stimulation | +23% in lateral-hypothalamic pedal presses | Reported relative increase; no direct statistical test versus Oleyl-Cortagen supplied in narrative. |
| Cortagen and Cerebrolysin · self-stimulation | No change reported in pedal-press frequency | At the systemic doses in this article; does not contradict the separate central-dose comparisons. |
| Open-field behavior | Oleyl-Cortagen increased horizontal and vertical movement but halved hole exploration | Cortexin and Cerebrolysin increased horizontal movement; Dilept reduced horizontal and vertical movement. |
| Noopept, Semax, Selank and Dilept · vertical activity | Reduced vertical movements reported | Compound-specific rat behavior at the stated doses, not a measure of human alertness. |
| Porsolt immobility | Lower with Oleyl-Cortagen, Dilept and Cortexin; higher with Cerebrolysin, Semax, Cortagen and Selank | This unweighted behavior assay is distinct from loaded endurance swimming. Piracetam was inactive in the report. |
| Deltaran · grooming | Grooming reactions increased | The report tested Deltaran, a DSIP-containing formulation; this observation is not assigned to isolated DSIP. |
Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
- Source reviewed
- Publisher full-text methods and results narrative; original PDF tables not recovered
Study limitations
- Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery.
- Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred.
- The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.
Reviewed 2026-11-08.
Animal research · 1999
DSIP across hypoxia, swimming, immobilization and audiogenic stress
The author describes brain monoamine changes observed up to five days after a DSIP injection and delayed fatigue in forced swimming.
Monoamine time course · Selected changes observed for up to 5 days after an injection · Measurements of brain neurochemistry; not drug exposure or human duration of action.
Study notes and original source
DSIP across hypoxia, swimming, immobilization and audiogenic stress
· Dissertation
Format: Accessible dissertation or author-abstract transcription; full scan and original tables not recovered · Reviewed: Reported methods, results and evidence limitations
D. V. Alperovich · Rostov-on-Don doctoral dissertation, 338 pp.
The author describes brain monoamine changes observed up to five days after a DSIP injection and delayed fatigue in forced swimming.
Results and tables
Reported findings and study design
The author describes brain monoamine changes observed up to five days after a DSIP injection and delayed fatigue in forced swimming.
Animal experiments in multiple stress models; group counts not verified in accessible text
Population or model Animal experiments in multiple stress models; group counts not verified in accessible text
Protocol information
The dissertation excerpt describes a single pretreatment injection in selected series. Exact dose, route and timing by series were not recovered.
Protocol source ↗ · Accessible dissertation or author-abstract transcription; full scan and original tables not recovered
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Monoamine time course | Selected changes observed for up to 5 days after an injection | Measurements of brain neurochemistry; not drug exposure or human duration of action. |
| Forced swimming | Longer time before fatigue described | No verified numerical swim-time contrast in accessible conclusions. |
| Other stress models | Changes in leukocyte pattern, lipid peroxidation and membrane measures | Hypoxia, restricted movement and audiogenic stress; distinct experiments. |
An archival stress-response hypothesis. Exact effects and dose schedules remain unresolved.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Animal experiments in multiple stress models; group counts not verified in accessible text
- Source reviewed
- Accessible dissertation or author-abstract transcription; full scan and original tables not recovered
Study limitations
- Five days refers to observation of selected biochemical changes, not measured half-life or five days of benefit.
- Swimming time and survival magnitudes and adverse effects require full results tables.
Reviewed 2026-11-08.
Animal research · 2004
DSIP analogues ID-1, ID-3 and ID-8 in age-stratified rat stress models
The dissertation describes analogue- and age-dependent changes in leukocytes, oxidative markers and chromosome damage. ID-3 and piracetam were highlighted in older rats.
Study notes and original source
DSIP analogues ID-1, ID-3 and ID-8 in age-stratified rat stress models
· Dissertation
Format: Accessible dissertation or author-abstract transcription; full scan and original tables not recovered · Reviewed: Reported methods, results and evidence limitations
E. I. Rakhmanova · Candidate dissertation, 152 pp.; Makhachkala author abstract, 22 pp.
The dissertation describes analogue- and age-dependent changes in leukocytes, oxidative markers and chromosome damage. ID-3 and piracetam were highlighted in older rats.
Results and tables
Reported findings and study design
The dissertation describes analogue- and age-dependent changes in leukocytes, oxidative markers and chromosome damage. ID-3 and piracetam were highlighted in older rats.
Rats of different ages under intact and restricted-movement conditions; DSIP and piracetam served as distinct comparators
Population or model Rats of different ages under intact and restricted-movement conditions; DSIP and piracetam served as distinct comparators
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Analogue identities | ID-1, ID-3 and ID-8 tested separately from parent DSIP and piracetam | Analogue codes are reported; sequence-level identity was not independently resolved. |
| Age and oxidative response | ID-3 and piracetam were highlighted in old rats, including slower MDA formation | Qualitative conclusions only; no verified magnitude. |
| Other endpoints | Leukocyte profile and chromosomal-aberration outcomes varied by analogue and age | Restricted-movement model; biochemical and cytogenetic effects rather than sport performance. |
The primary value is a lead for analogue-specific research; the parent peptide and analogues remain distinct.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Rats of different ages under intact and restricted-movement conditions; DSIP and piracetam served as distinct comparators
- Source reviewed
- Accessible dissertation or author-abstract transcription; full scan and original tables not recovered
Study limitations
- Sequence identities, exact comparative estimates and doses need original table recovery.
- The activity of these analogues does not establish an effect of DSIP itself or efficacy in humans.
Reviewed 2026-11-08.
Animal research · 2014
Pinealon, Cortexin and Deltaran: prenatal-stress conference findings
Deltaran, a DSIP-containing preparation with glycine, had 96% reported offspring survival in the 2014 conference abstract. Group sizes and an untreated-hypoxia survival rate are missing; the biochemical result is internally contradictory.
Study notes and original source
Pinealon, Cortexin and Deltaran: prenatal-stress conference findings
Cortexin mixture, Pinealon and Deltaran (DSIP-containing formulation); separate groups · Conference abstract
Format: Original PDF · Reviewed: Original congress proceedings reproduced by an academic repository; printed pp.233–234 visually checked
A. M. Mendzheritskii, G. V. Karantysh · X International Congress “Neuroscience for Medicine and Psychology”, Sudak, 2–12 June 2014, pp.233–234
The abstract reports 96% survival with Deltaran and 94% with Pinealon, without denominators or an untreated-hypoxia survival rate. Learning favored Deltaran then Pinealon then Cortexin, but contradictory caspase-3 statements remain unresolved.
Results and tables
Reported findings and study design
Reported findings
The abstract reports 96% survival with Deltaran and 94% with Pinealon, without denominators or an untreated-hypoxia survival rate. Learning favored Deltaran then Pinealon then Cortexin, but contradictory caspase-3 statements remain unresolved.
Maternal intraperitoneal exposure throughout pregnancy. Daily hypobaric hypoxia on gestation days 13–20, 66.41 kPa for three hours. Offspring Morris maze and cortical/brainstem caspase-3 at day 21.
Population or model 21-day-old outbred rat offspring; seven listed treatment groups; no group sizes supplied
Dose, route and schedule
Maternal doses as printed: Cortexin 1 mg/kg, Pinealon 10 µg/kg, Deltaran 12 µg/100 g body weight; intraperitoneally throughout gestation. The abstract does not resolve whether Deltaran mass means formulation or active peptide. These are historical animal methods.
Protocol source ↗ · Original congress proceedings reproduced by an academic repository; printed pp.233–234 visually checked
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported survival | Deltaran 96%; Pinealon 94% | No n, uncertainty, untreated-hypoxia rate or numerical Cortexin survival supplied |
| Latent learning | Authors rank Cortexin < Pinealon < Deltaran | No group mean latency, variance or between-treatment p-values |
| Caspase-3 conflict | Deltaran+hypoxia is described as +144% in cortex and +109% in brainstem, then as remaining at control level | Both statements occur in the same abstract; do not resolve by assumption · First sentence: p<0.0001 and p<0.001, respectively |
| Comparator gap | Seven-group list lacks a hypoxia-only untreated arm | An omitted group may exist, but it cannot be reconstructed from the abstract |
Conference abstract with missing denominators and an internally inconsistent biochemical result; not a clinical trial. Deltaran is a DSIP-containing formulation with glycine; results are not proof for isolated DSIP. Formulation mass versus active-peptide mass is not resolved by this abstract. Shared Rostov authors and models may overlap the 2012 papers and dissertations; no pooled sample or independent-replication count is calculated.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- 21-day-old outbred rat offspring; seven listed treatment groups; no group sizes supplied
- Source reviewed
- Original congress proceedings reproduced by an academic repository; printed pp.233–234 visually checked
Study limitations
- Conference abstract with missing denominators and an internally inconsistent biochemical result; not a clinical trial.
- Deltaran is a DSIP-containing formulation with glycine; results are not proof for isolated DSIP. Formulation mass versus active-peptide mass is not resolved by this abstract.
- Shared Rostov authors and models may overlap the 2012 papers and dissertations; no pooled sample or independent-replication count is calculated.
Reviewed 2026-11-08.
Controlled study in people · 1981
Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
In a double-blind crossover experiment, median total sleep time during the 130-minute post-infusion interval was 59% higher with DSIP than placebo. This was an acute sleep experiment in six healthy volunteers.
Study notes and original source
Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
· Original journal report
Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA · Int J Clin Pharmacol Ther Toxicol 19:341-345
In a double-blind crossover experiment, median total sleep time during the 130-minute post-infusion interval was 59% higher with DSIP than placebo. This was an acute sleep experiment in six healthy volunteers.
Results and tables
Reported findings and study design
In a double-blind crossover experiment, median total sleep time during the 130-minute post-infusion interval was 59% higher with DSIP than placebo. This was an acute sleep experiment in six healthy volunteers.
Population or model 6 healthy volunteers: 4 men and 2 women.
Dose, route and schedule
Slow morning intravenous DSIP infusion, 25 nmol/kg, versus placebo. Historical study methods, not personal-use instructions.
Protocol source ↗ · Indexed abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Median total sleep time | 59% higher than placebo | 130-minute post-infusion interval |
| Participants | 6 healthy volunteers |
No absolute sleep-duration values or confidence interval are provided in the abstract. A six-person experiment cannot establish long-term insomnia treatment effects.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 6 healthy volunteers: 4 men and 2 women.
- Source reviewed
- Primary indexed abstract and publication metadata checked through Europe PMC on 1 November 2026. Full-text methods not reviewed.
Study limitations
- No absolute sleep-duration values or confidence interval are provided in the abstract.
- A six-person experiment cannot establish long-term insomnia treatment effects.
Reviewed 2026-11-01.
Comparison in people · 1993
Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women
DSIP did not change spontaneous or arginine-stimulated growth hormone or prolactin secretion. The placebo-comparison subset comprised three women.
Study notes and original source
Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women
· Original journal report
Giusti M, Carraro A, Porcella E, Valenti S, Nicora D, Sessarego P, Giordano G · Psychoneuroendocrinology 18:79-84
DSIP did not change spontaneous or arginine-stimulated growth hormone or prolactin secretion. The placebo-comparison subset comprised three women.
Results and tables
Reported findings and study design
DSIP did not change spontaneous or arginine-stimulated growth hormone or prolactin secretion. The placebo-comparison subset comprised three women.
Population or model 8 healthy women overall; only 3 entered the DSIP-versus-placebo circadian comparison.
Dose, route and schedule
In the three-woman circadian comparison, DSIP 25 micrograms/kg intravenously from 21:30 to 22:30 versus placebo infusion. Historical study methods, not personal-use instructions.
Protocol source ↗ · Indexed abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Growth hormone and prolactin | No change in secretion or circadian rhythm | |
| Placebo-comparison subset | 3 women | 8 women participated across all experiments |
Five other women underwent arginine challenge conditions; eight is not the placebo-comparison sample size. Randomization and masking are not stated in the abstract.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 8 healthy women overall; only 3 entered the DSIP-versus-placebo circadian comparison.
- Source reviewed
- Primary indexed abstract and publication metadata checked through Europe PMC on 1 November 2026. Full-text methods not reviewed.
Study limitations
- Five other women underwent arginine challenge conditions; eight is not the placebo-comparison sample size.
- Randomization and masking are not stated in the abstract.
Reviewed 2026-11-01.
Animal research · 1997
Studies of the mechanism of the anticonvulsant effect of delta-sleep-inducing peptide in conditions of increased oxygen tension.
An intraperitoneal DSIP dose of 12 μg per 100 g body weight delayed generalized convulsions by 2–2.5-fold in a hyperbaric oxygen experiment. This English report may overlap the 1996 Russian publication.
Study notes and original source
Studies of the mechanism of the anticonvulsant effect of delta-sleep-inducing peptide in conditions of increased oxygen tension.
Preparation-specific research; no equivalence inferred
Mendzheritskii AM, Lysenko AV, Uskova NI, Sametskii EA. · Neuroscience and behavioral physiology
An intraperitoneal DSIP dose of 12 μg per 100 g body weight delayed generalized convulsions by 2–2.5-fold in a hyperbaric oxygen experiment. This English report may overlap the 1996 Russian publication.
Results and tables
Reported findings and study design
Investigators varied three DSIP doses and the timing before compression in a chamber to an oxygen tension of 0.7 MPa.
Population or model Animal hyperbaric oxygen experiment. The abstract gives no arm sizes.
Dose, route and schedule
The abstract identifies 12 μg per 100 g (120 μg/kg) intraperitoneally as the most effective dose tested. It does not give the other doses or exact pretreatment intervals.
Protocol source ↗ · Original paper abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Onset of generalized convulsions | 2–2.5-fold delay with DSIP at 12 μg per 100 g | At 0.7 MPa oxygen tension |
| Sleep–wake cycle | The investigators reported recovery toward normal cycling within 24 hours after hyperbaric oxygen exposure. |
The English paper may correspond to the earlier Russian publication. The experiment concerns oxygen-induced convulsions in animals.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- Animal hyperbaric oxygen experiment. The abstract gives no arm sizes.
- Source reviewed
- Original paper abstract
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-11-16.
Controlled study in people · 1987
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.
A 14-person placebo-controlled insomnia report described improved sleep and daytime performance over seven nights of DSIP, without giving numerical sleep or performance effect sizes in its abstract.
Study notes and original source
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.
Ordinary DSIP
Schneider-Helmert D · European neurology 27(2):120-129
A 14-person placebo-controlled insomnia report described improved sleep and daytime performance over seven nights of DSIP, without giving numerical sleep or performance effect sizes in its abstract.
Results and tables
Reported findings and study design
A 14-person placebo-controlled insomnia report described improved sleep and daytime performance over seven nights of DSIP, without giving numerical sleep or performance effect sizes in its abstract.
14 middle-aged chronic insomniacs; double-blind placebo-controlled administration and polysomnography.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Sleep and daytime performance | Reported improvements; numerical changes not supplied | Sleep effects reportedly persisted on the first placebo post-treatment night |
| Participants | 14 chronic-insomnia patients | |
| Observation schedule | 7 successive treatment nights; daytime testing before and after 6 injections |
This positive report is shown alongside the separate weak/neutral DSIP comparisons; their findings should not be pooled without full methods.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 14 middle-aged patients with chronic insomnia
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Small sample and short follow-up; allocation and complete methods require appraisal.
Reviewed 2026-11-01.
Controlled study in people · 1987
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.
A double-blind crossover study found little clinically significant sleep improvement with DSIP; some nominal sleep-stage differences were already present at baseline.
Study notes and original source
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.
Ordinary DSIP
Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D · International journal of clinical pharmacology research 7(2):105-110
A double-blind crossover study found little clinically significant sleep improvement with DSIP; some nominal sleep-stage differences were already present at baseline.
Results and tables
Reported findings and study design
A double-blind crossover study found little clinically significant sleep improvement with DSIP; some nominal sleep-stage differences were already present at baseline.
Insomnia patients studied over four nights with polysomnography; sample size not stated in the abstract.
Population or model Patients with chronic insomnia; double-blind crossover
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Awakenings and wake time | Decreased during DSIP, without significant baseline or placebo differences | Also applies to NREM latency and waking after sleep onset |
| NREM and stage 2 sleep | Nominal differences versus placebo, with the same differences already present at baseline | |
| Slow-wave and REM sleep | Not modified | |
| Studied exposure | 25 nmol/kg intravenously; four-night crossover |
The abstract contains no sleep-duration effect sizes or arm-level counts. Its conclusion is limited clinical significance.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- Patients with chronic insomnia; double-blind crossover
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Baseline differences complicate interpretation; sample size is not provided in the indexed abstract.
Reviewed 2026-11-01.
Controlled study in people · 1992
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.
In 16 chronic-insomnia patients, DSIP produced weak objective sleep differences and no consistent subjective sleep benefit; the authors found little likely therapeutic value.
Study notes and original source
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.
Ordinary DSIP
Bes F, Hofman W, Schuur J, Van Boxtel C · Neuropsychobiology 26(4):193-197
In 16 chronic-insomnia patients, DSIP produced weak objective sleep differences and no consistent subjective sleep benefit; the authors found little likely therapeutic value.
Results and tables
Reported findings and study design
In 16 chronic-insomnia patients, DSIP produced weak objective sleep differences and no consistent subjective sleep benefit; the authors found little likely therapeutic value.
Double-blind matched-pairs parallel comparison: 8 DSIP, 8 glucose placebo; five laboratory nights.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Objective sleep | Higher efficiency and shorter latency, described as weak effects | Authors note possible contribution from incidental placebo-group changes |
| Subjective sleep quality | No change | No numerical sleep-minute difference in the abstract |
| Participants | 8 DSIP; 8 placebo | |
| Studied schedule | 25 nmol/kg IV before nights 3, 4 and 5 |
Design figures are available; objective effect sizes in minutes and confidence intervals are not. The original authors did not infer a major therapeutic benefit.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 16 patients; double-blind matched-pairs parallel groups
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Small, brief study; selected statistically significant endpoints do not establish a meaningful overall benefit.
Reviewed 2026-11-01.
Animal research · 1995
[Ratio of neuromediator amino acids in a comparative analysis of the stress protective effects of delta-sleep inducing peptide and piracetam].
Combined DSIP and piracetam administration was associated with stronger stress-related effects on the balance of inhibitory and excitatory amino acids than individual compounds.
Study notes and original source
[Ratio of neuromediator amino acids in a comparative analysis of the stress protective effects of delta-sleep inducing peptide and piracetam].
DSIP + piracetam
Mendzheritskiĭ AM, Uskova NI, Lysenko AV, Matsionis AE, Sametskiĭ EA · Voprosy meditsinskoi khimii 41(5):16-19
Combined DSIP and piracetam administration was associated with stronger stress-related effects on the balance of inhibitory and excitatory amino acids than individual compounds.
- Population / setting
- Rats exposed to one-hour restricted movement
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Biochemical animal endpoints; no evidence of human cognitive or occupational benefit. Full data are needed to assess additivity versus synergy.
Reviewed 2026-10-01.
Animal research · 1999
Metabolic features of the adaptive effect of delta-sleep inducing peptide and piracetam under hyperoxic conditions.
The combination enhanced reported protection alongside changes in neurotransmitter amino acids, membrane ATPase activity and lipid-peroxidation products.
Study notes and original source
Metabolic features of the adaptive effect of delta-sleep inducing peptide and piracetam under hyperoxic conditions.
Author affiliations · Neurocybernetics Institute, Rostov State University
DSIP + piracetam
Lysenko AV, Alperovich DV, Uskova NI, Mendzheritsky AM · Biochemistry. Biokhimiia 64(6):652-657
The combination enhanced reported protection alongside changes in neurotransmitter amino acids, membrane ATPase activity and lipid-peroxidation products.
Results and tables
Reported findings and study design
Rat cortical-membrane experiment: single IP DSIP 12 micrograms/100 g and IP piracetam 3 mg/100 g/day for three days; hyperbaric oxygen 0.3 MPa for two hours.
Population or model Rats exposed to hyperbaric oxygen at 0.3 MPa for two hours
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Combination response | Greater protection than individual treatments reported | No numerical biochemical effect size supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rats exposed to hyperbaric oxygen at 0.3 MPa for two hours
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Hyperoxia is excess oxygen, not oxygen deprivation. These animal findings do not establish a human diving, sleep or performance regimen.
Reviewed 2026-10-01.
Animal research · 1995
[Proteolytic processes in the rat brain and serum in hypokinesia and the adaptive effect of delta-sleep inducing peptide].
DSIP changed proteolytic enzyme activity and was reported to prevent lysosomal-membrane permeability disturbances during prolonged restricted movement.
Study notes and original source
[Proteolytic processes in the rat brain and serum in hypokinesia and the adaptive effect of delta-sleep inducing peptide].
Ordinary DSIP
Mendzheritskiĭ AM, Lysenko AV, Uskova NI · Biokhimiia (Moscow, Russia) 60(4):585-592
DSIP changed proteolytic enzyme activity and was reported to prevent lysosomal-membrane permeability disturbances during prolonged restricted movement.
- Population / setting
- Rat brain and serum under hypokinesia
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Proposed preadaptation through regulatory-peptide metabolism is a mechanistic interpretation, not a demonstrated human effect.
Reviewed 2026-10-01.
Animal research · 1996
[The mechanism of the anticonvulsive effect of the delta sleep-inducing peptide under conditions of elevated oxygen pressure].
The authors reported seizure protection accompanied by higher cortical GABA and homocarnosine and lower glutamate and aspartate.
Study notes and original source
[The mechanism of the anticonvulsive effect of the delta sleep-inducing peptide under conditions of elevated oxygen pressure].
Ordinary DSIP
Mendzheritskiĭ AM, Lysenko AV, Uskova NI, Sametskiĭ EA · Fiziologicheskii zhurnal imeni I.M. Sechenova 82(1):59-64
The authors reported seizure protection accompanied by higher cortical GABA and homocarnosine and lower glutamate and aspartate.
- Population / setting
- Rats under elevated oxygen pressure
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Oxygen-toxicity model; not evidence for treating human epilepsy or oxygen deprivation.
Reviewed 2026-10-01.
Animal research · 1986
[Active analog of the inactive "sleep peptide"].
The D-Trp¹ analogue increased slow-wave sleep under the reported conditions; central administration also raised body temperature.
Rectal temperature · 0.9 °C increase · p<0.01
Study notes and original source
[Active analog of the inactive "sleep peptide"].
D-Trp¹-DSIP analogue
Koval'zon VM, Kalikhevich VN, Churkina SI · Biulleten' eksperimental'noi biologii i meditsiny 101(6):707-709
The D-Trp¹ analogue increased slow-wave sleep under the reported conditions; central administration also raised body temperature.
Results and tables
Reported findings and study design
Rabbit study of the modified (D-Trp¹)DSIP analogue, not parent DSIP; central doses 0.7, 7 or 70 micrograms/kg.
Population or model Rabbits; central and intravenous analogue administration
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Slow-wave sleep after central administration | 40% increase over three daylight hours | p<0.01 |
| Rectal temperature | 0.9 °C increase | p<0.01 |
| Slow-wave sleep after IV analogue | 25% increase at 30–70 micrograms/kg |
The positive figures belong to the D-Trp analogue; parent DSIP’s sleep-inducing properties were not demonstrated in this report.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rabbits; central and intravenous analogue administration
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Modified peptide, not ordinary DSIP. Route, narrow effective range and species constrain extrapolation.
Reviewed 2026-10-01.
Animal research · 1986
Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep.
Ordinary DSIP did not increase sleep. D-Trp¹ and D-Tyr¹ analogues promoted sleep, while a shortened D-Trp¹ fragment produced arousal.
Study notes and original source
Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep.
DSIP and modified analogues
Obál F Jr, Kovalzon VM, Kalikhevich VN, Török A, Alföldi P, Sáry G, Hajós M, Penke B · Pharmacology, biochemistry, and behavior 24(4):889-894
Ordinary DSIP did not increase sleep. D-Trp¹ and D-Tyr¹ analogues promoted sleep, while a shortened D-Trp¹ fragment produced arousal.
- Population / setting
- Rats; intracerebroventricular administration
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Structure and experimental timing matter. Central animal administration cannot be transferred to commercial DSIP products.
Reviewed 2026-10-01.
Animal research · 1986
[Peptidergic modulation of sleep: a comparative study of analogs of the peptide DSIP].
Full-length modified analogues increased sleep; the shortened fragment reduced slow-wave sleep in rats but had no effect in rabbits.
Study notes and original source
[Peptidergic modulation of sleep: a comparative study of analogs of the peptide DSIP].
DSIP analogues
Koval'zon VM, Obál F Jr, Kalikhevich VN · Zhurnal evoliutsionnoi biokhimii i fiziologii 22(5):483-488
Full-length modified analogues increased sleep; the shortened fragment reduced slow-wave sleep in rats but had no effect in rabbits.
- Population / setting
- Rabbits and rats; implanted electrodes and cannulas
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Potential overlap with related 1986 experiments needs full-text comparison; not automatically independent replication.
Reviewed 2026-10-01.
Animal research · 2001
[Hypnogenic properties of DSIP peptide analogs: structural-functional relationship].
Ordinary DSIP and most analogues had no significant effect. N-MeAla² and Pro² analogues increased slow-wave sleep, whereas β-Ala² suppressed it.
Study notes and original source
[Hypnogenic properties of DSIP peptide analogs: structural-functional relationship].
Author affiliations · Severtsov Institute of Ecology and Evolution, Russian Academy of Sciences
DSIP and 13 analogues
Koval'zon VM · Izvestiia Akademii nauk. Seriia biologicheskaia (4):467-474
Ordinary DSIP and most analogues had no significant effect. N-MeAla² and Pro² analogues increased slow-wave sleep, whereas β-Ala² suppressed it.
Results and tables
Reported findings and study design
Rabbits with implanted electrodes; parent DSIP and 13 analogues administered into the lateral ventricle; daytime recording 7–12 hours.
Population or model Rabbits; DSIP and 13 synthetic analogues
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Parent DSIP and most analogues | No significant sleep change | |
| [NMeAla²]DSIP and [Pro²]DSIP | Slow-wave sleep proportion increased about 10–15% | |
| [β-Ala²]DSIP | Sleep suppressed |
Analogue-specific effects must not be assigned to parent DSIP.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rabbits; DSIP and 13 synthetic analogues
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Intracerebroventricular animal experiment. The English translation is the same publication, not another study.
Reviewed 2026-10-01.
Animal research · 1977
Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.
The Basel group characterized the nine-amino-acid sequence and reported delta/spindle EEG enhancement with synthetic DSIP in its assay.
Study notes and original source
Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.
Synthetic DSIP and comparison peptides
Schoenenberger GA, Monnier M · Proceedings of the National Academy of Sciences of the United States of America 74(3):1282-1286
The Basel group characterized the nine-amino-acid sequence and reported delta/spindle EEG enhancement with synthetic DSIP in its assay.
- Population / setting
- 58 rabbits including controls; peptide characterization
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Historical rabbit assay, not clinical validation. Later studies produced inconsistent sleep findings.
Reviewed 2026-10-01.
Observational study · 1983
Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.
An uncontrolled withdrawal report described improvement in 48 of 49 evaluable patients after DSIP, but 18 of 67 enrolled patients were not evaluable.
Study notes and original source
Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.
Ordinary DSIP
Dick P, Grandjean ME, Tissot R · Neuropsychobiology 10(4):205-208
An uncontrolled withdrawal report described improvement in 48 of 49 evaluable patients after DSIP, but 18 of 67 enrolled patients were not evaluable.
Results and tables
Reported findings and study design
An uncontrolled withdrawal report described improvement in 48 of 49 evaluable patients after DSIP, but 18 of 67 enrolled patients were not evaluable.
67 patients with withdrawal symptoms: alcohol 28, opiates 39; DSIP was the sole reported treatment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported beneficial response | 48/49 evaluable | 22 alcohol-withdrawal patients and 26/27 opiate-withdrawal patients |
| Attrition | 18/67 not evaluable; abstract reports 27% | 49 patients contributed to the response analysis |
| Major adverse effects | None reported | Limited uncontrolled clinical series |
| Studied regimen | 25 nmol/kg intravenously |
The evaluable-patient response excludes substantial attrition and has no placebo comparator. It does not establish a safe or effective withdrawal treatment.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 67 withdrawal patients enrolled; 49 evaluable
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- No control group and substantial exclusion/loss prevent causal conclusions. Not a basis for self-treatment of withdrawal.
Reviewed 2026-11-01.
Review of earlier studies · 1986
Delta-sleep-inducing peptide (DSIP): an update.
Reviews sleep and non-sleep research, including pain, withdrawal and DSIP-like material. Physiological roles and mechanisms were unresolved.
Study notes and original source
Delta-sleep-inducing peptide (DSIP): an update.
DSIP literature
Graf MV, Kastin AJ · Peptides 7(6):1165-1187
Reviews sleep and non-sleep research, including pain, withdrawal and DSIP-like material. Physiological roles and mechanisms were unresolved.
- Population / setting
- Historical animal and human literature
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- Historical synthesis, not a new clinical cohort or current comprehensive safety review.
Reviewed 2026-10-01.
Review of earlier studies · 2006
Delta sleep-inducing peptide (DSIP): a still unresolved riddle.
The authors questioned the identity and physiological role of endogenous DSIP and distinguished the parent peptide from active analogues and DSIP-like immunoreactivity.
Study notes and original source
Delta sleep-inducing peptide (DSIP): a still unresolved riddle.
Author affiliations · Severtsov Institute of Ecology and Evolution, Russian Academy of Sciences
DSIP, analogues and DSIP-like material
Kovalzon VM, Strekalova TV · Journal of neurochemistry 97(2):303-309
The authors questioned the identity and physiological role of endogenous DSIP and distinguished the parent peptide from active analogues and DSIP-like immunoreactivity.
- Population / setting
- Critical historical and experimental synthesis
- Source reviewed
- Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Study limitations
- This is the authors’ 2006 assessment, not a claim that a modern exhaustive receptor or gene search has been completed.
Reviewed 2026-10-01.
Explore related historical combinations ↗
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗